NBTX vs PD: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

NBTX (Nanobiotix) and PD (PagerDuty) share investment themes but are different businesses. If you believe in growth, NBTX fits: analysts expect its revenue to rise 95% next year, against 2% for PD. If you believe in profit, PD fits: it is expected to make money next year (10.29x forward earnings), while NBTX is still expected to post a loss.

NBTX vs PD: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricNBTXPDWhat it tells you
Market cap$1.37B$1.19BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-159.7810.29Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta0.540.95Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range20% of range76% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.

Before you buy: how NBTX and PD affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. NBTX and PD share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined NBTX and PD exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Nanobiotix (NBTX) do?

Nanobiotix S.A. is a clinical-stage nanomedicine company headquartered in France and dual-listed on Nasdaq (as American Depositary Shares under NBTX) and Euronext Paris. Its lead product candidate, NBTXR3 (also called JNJ-1900), is a radioenhancer: injectable nanoparticles that are placed directly into a tumor and, when activated by standard radiotherapy, are designed to boost the radiation's tumor-killing effect. In late 2023 the company signed a global license and collaboration with Johnson & Johnson's Janssen unit, which now sponsors and operates the registrational Phase 3 NANORAY-312 study in head and neck cancer and broader development across other solid tumors.

Full NBTX guide

What does PagerDuty (PD) do?

PagerDuty sells the software that wakes engineers up. When a payment system, a checkout flow or an internal API breaks, PagerDuty ingests the alert from monitoring tools, decides who is on call, escalates until a human acknowledges it, and coordinates the response through to a postmortem. Around that core it has added runbook automation (from its 2020 Rundeck purchase), an AIOps layer that groups noisy alerts into single incidents, customer service operations tooling, and more recently a set of agentic features: in November 2026 it unveiled Paige, an SRE agent, alongside a rebranded PD Reliability Platform and a PD Labs unit for open AI work in reliability engineering. Roughly 15,500 paying customers use it, of which about 884 spend more than ~$100,000 a year, and annual recurring revenue sits near ~$501 million.

Full PD guide

NBTX vs PD: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • NBTX drivers: Johnson & Johnson partnership; NANORAY-312 head and neck readout.
  • PD drivers: Margin and cash generation from a flat revenue base; A new chief executive and a go-to-market reset.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant risk is clinical and binary: NBTXR3 remains unapproved, and a failed or delayed NANORAY-312 Phase 3 could erase much of the equity value in a single day. For PD, the core problem is demand, not costs: dollar-based net retention of ~98% means the existing customer base is shrinking slightly net of expansion, so new logos are doing the work of holding revenue flat.

NBTX or PD: which should you pick?

If the story you believe is NBTX's (Johnson & Johnson partnership), NBTX is the more direct way to own it; if it is PD's (Margin and cash generation from a flat revenue base), PD is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the NBTX and PD guides.

NBTX vs PD: the full fundamentals

NBTX. Standard price-to-earnings valuation does not apply because Nanobiotix is pre-approval and its reported revenue stems mostly from the J&J agreement rather than product sales. The market instead prices the probability-weighted value of NBTXR3 across head and neck, lung, melanoma and other tumors, net of dilution risk; that value fell from roughly $1.5 billion in mid-2026 to about $1.1 billion by mid-October, then recovered to ~$1.37 billion by November 20 after the melanoma data. The three analysts with targets on Yahoo Finance averaged about $53, roughly double the current price, a gap typical of binary-outcome biotechs.

PD. Two numbers explain most of the debate around PD. Revenue growth under 1% with retention below 100% is what kept the multiple under ~2x sales through the summer, while a ~23.7% non-GAAP operating margin and real free cash flow are what kept a floor under it. At about $15.08 (November 20, 2026) the stock trades near 2.4x sales and about 10x analysts' forward EPS of ~$1.47, somewhat below the mid-October peak multiple. Consensus for fiscal 2027 is ~$1.36 of EPS on ~$494 million of revenue, so profitability is expected to do the improving, and the December 3 report will show whether that holds.

Headline figures (approximate, November 2026): NBTX shows market cap ~$1.37 billion (close ~$26.80 on Nov 20, 2026), revenue (ttm) ~$11.5 million (largely J&J-agreement, non-product), revenue growth ~-79% year over year in H1 2026 (EUR 5.6M vs EUR 26.6M, which had a one-off item), net loss (ttm) ~$53 million; PD shows revenue (ttm) ~$495 million, q2 fy2027 revenue (quarter ended july 31, 2026) ~$124.4 million, up ~0.8% year over year, annual recurring revenue / net retention ~$501 million ARR, dollar-based net retention ~98%, profitability ~85% gross margin; GAAP operating margin ~6.8% (TTM); non-GAAP operating margin ~23.7% last quarter; non-GAAP diluted EPS ~$0.32 (est. ~$0.31).

The bottom line: NBTX vs PD

NBTX and PD are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined NBTX and PD exposure against your real portfolio. It is not an investment adviser.

Wondering how NBTX or PD fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Nanobiotix

Ask Walnut's AI anything about NBTX and see how it fits what you own.

FAQ

What is the difference between NBTX and PD?

+

Nanobiotix S.A. PagerDuty sells the software that wakes engineers up. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is NBTX or PD the better stock?

+

Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, NBTX or PD?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both NBTX and PD?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of NBTX vs PD?

+

NBTX: The dominant risk is clinical and binary: NBTXR3 remains unapproved, and a failed or delayed NANORAY-312 Phase 3 could erase much of the equity value in a single day. As a clinical-stage biotech, Nanobiotix funds itself through partnership payments and equity raises, so continued losses and further share dilution are likely until (and unless) a product is approved. The valuation of roughly $1.37 billion (November 2026) still embeds substantial expectation of success, leaving little margin for disappointment. Concentration is acute because a large share of value depends on one molecule and one partner, so a strategic shift by J&J would be highly damaging. The NANORAY-312 amendment that cut the interim analysis and reduced the planned number of events speeds the readout but could affect the trial's statistical power. Being a foreign issuer listed via ADS also adds currency, reporting-timing, and liquidity considerations for U.S. holders. The stock's ~35% drop over the three months to November 20, 2026, even after a bounce on early-stage melanoma data, shows how sharply sentiment can move without a registrational result. Early single-arm data, like the melanoma study, can move the shares but does not establish efficacy. PD: The core problem is demand, not costs: dollar-based net retention of ~98% means the existing customer base is shrinking slightly net of expansion, so new logos are doing the work of holding revenue flat. Seat-based pricing ties PagerDuty to engineering headcount at technology companies, a line item that has been cut repeatedly since 2023 and that AI coding tools may keep suppressing. Competitively, the pressure comes from bundling rather than from a better product: Datadog now ships its own on-call module, Atlassian folds Opsgenie capability into Jira Service Management, and both can price incident management as an add-on to a platform a customer already buys. Glancy Prongay & Murray announced a securities-fraud investigation in December 2025 after the November 25, 2025 results, when the shares fell about 23% on disclosure of weakening demand and retention, and while no class action complaint has been filed to date, the underlying facts it points at are the same growth facts above. Convertible debt sits against the cash balance (Yahoo Finance shows about ~$413 million of debt versus ~$470 million of cash and investments), so the gross cash figure overstates the net position, and any reader should check the current note terms in the latest 10-Q rather than assume them away. Valuation risk has also risen: even after a one-month pullback of about 14% the stock trades above the average analyst target of about $13.43, and the trailing P/E of about 7.5x flatters it because trailing net income of ~$186 million includes a single quarter of about $160 million in late 2025, far above the ~$5 million to ~$11 million of recent quarters.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell NBTX or PD; figures are approximate and dated (as of November 2026). Verify current data before investing.